Oragenics' "Listing Update" Is a Second Delisting Warning

The press release that crossed my screen this morning has three clauses: continued clinical progress, a regulatory update, and a "NYSE American listing update." Two of those read like good news. The third is a delisting warning wearing a bland word. On August 26 the exchange told Oragenics that its stockholders' equity no longer meets NYSE American's continued listing standards — the second time in roughly ten months that this company has fallen below them. The shares, worth about $2.3 million in total and sitting near the bottom of their 52-week range, are the kind of small, beaten-down name retail chat rooms love to ring the bell on.

This is where I normally stop. I don't underwrite clinical-stage biotechs, and this one fails my checklist on the first line: no product revenue, no free cash flow, and none coming while the trial runs. But the update is worth a few minutes because it is a clean example of how a headline buries the number that matters. So let's read all three clauses the way a lender would.

The "listing update" is the news

The letter, dated August 26, cites two NYSE American equity tests. Section 1003(a)(ii) requires $4 million of stockholders' equity if a company lost money in three of its past four fiscal years; Section 1003(a)(iii) requires $6 million if it lost money in all five most recent ones. Oragenics has lost money in each of the last five fiscal years and reported just $3.7 million of stockholders' equity at June 30 — a deficit under both bars. It has 45 days to submit a compliance plan; if the exchange accepts it, the listing survives on a cure clock that runs to February 25, 2028. The release adds the standard hedge: there can be no assurances.

None of this is a paperwork hiccup, because it is the second lap around the same track. In October 2025 the company announced it had regained full compliance with these very standards — resolved after a $16.5 million offering of Series H convertible preferred closed in early July. Roughly a year later that money is mostly gone. At June 30 the company held $3.9 million in cash, and it used $4.4 million of cash running the business in the first half of the year. Its second-quarter net loss was $2.53 million, wider than the $2.27 million a year earlier. Simple arithmetic on that six-month cash burn: about five months of runway from the last balance-sheet date.

The "below cash" trap

This is the part that should make a value-minded reader slow down, because a sub-dollar biotech that trades below its own cash is exactly the pitch that pulls a few hundred shares out of a retail account. The total market value is roughly $2.3 million against $3.9 million of cash — about 90 cents of cash behind every roughly 52-cent share. Cheap is cheap, right?

The catch is what the share count ignores. That valuation counts only the common shares on the books — roughly 4.3 million of them. The company's May proxy disclosed that the outstanding Series H preferred stock could convert into roughly 15.5 million additional shares of common — about four times the current count — before the warrants, or another preferred issuance announced this spring, are even counted. Slice the same $3.9 million over a fully diluted count and the cash behind each share is closer to 20 cents. The "cheap against cash" story is an artifact of an incomplete count — and the fix for a listing deficiency is, by definition, more of the same: another financing at a market cap that only grows by printing. That machine has already been running a while: one-for-sixty reverse splits in 2023, one-for-thirty in 2025, and another split authorization put to shareholders this year.

Read the clinical clause honestly

The clinical clause is real, and I won't wave it off. The company reports nine participants dosed across three active Australian sites in a Phase IIa feasibility trial of ONP-002, an investigational nasal spray built on a neurosteroid, aimed at the brain swelling and inflammation that follow a concussion. Management says it is encouraged by the pace of enrollment, and it received FDA responses to a Type B meeting request while still targeting an Investigational New Drug filing — the formal application to start U.S. trials — by the end of this year. That is honest execution progress, and for a drug developer it matters.

But it is not financial proof. Nine patients in an open-label feasibility study — a small early test, not a registration trial — are years away from revenue, and the company expects to keep losing money while the balance sheet drains toward that IND filing. My method needs a hard financial bridge, and here there is none to point at. The only number that measures whether this company lives long enough to read its own data is cash divided by burn, and that number is heading down.

Why this fails the test I buy

Which is why this setup is the mirror image of the one I look for. My kind of opportunity is a stock where the market has already given up while the numbers underneath keep improving — tape pain without business pain. Here the market has given up, and the numbers have broken in the same direction: equity under the listing bar, cash down to a couple of quarters, a wider quarterly loss. When price and results break together, "beaten down" is not a discount. It is the price of the risk.

I can be wrong again, and a stock this far down can bounce hard on a headline. What would actually make the case concrete: cash that funds a real data read without a rescue raise, an IND actually on file, and a capital fix that clears the $6 million equity bar without ruinous dilution. What breaks it is already in writing — cash gone before data, another raise that only buys time, or a delisting process that starts. Until one of those changes, read this headline the way the company wrote it: progress to follow, not a reason to buy.